These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Molecular biology of intercalating agents used in tumor chemotherapy]. Hancock R Union Med Can; 1985 Sep; 114(9):755-7. PubMed ID: 4060347 [No Abstract] [Full Text] [Related]
6. Noble metal complexes in cancer chemotherapy. Rosenberg B Adv Exp Med Biol; 1977; 91():129-50. PubMed ID: 343531 [TBL] [Abstract][Full Text] [Related]
7. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model. Saucier JM; Yu J; Gaikwad A; Coleman RL; Wolf JK; Smith JA J Oncol Pharm Pract; 2007 Mar; 13(1):39-45. PubMed ID: 17621566 [TBL] [Abstract][Full Text] [Related]
8. Cisplatin and platinum drugs at the molecular level. (Review). Boulikas T; Vougiouka M Oncol Rep; 2003; 10(6):1663-82. PubMed ID: 14534679 [TBL] [Abstract][Full Text] [Related]
9. Platinum complexes: a new class of antineoplastic agents. Leh FK; Wolf W J Pharm Sci; 1976 Mar; 65(3):315-28. PubMed ID: 1263076 [No Abstract] [Full Text] [Related]
10. Covalent modification of DNA by antineoplastic agents. Hemminki K; Ludlum DB J Natl Cancer Inst; 1984 Nov; 73(5):1021-8. PubMed ID: 6387240 [No Abstract] [Full Text] [Related]
12. Preclinical perspectives on the use of platinum compounds in cancer chemotherapy. Farrell NP Semin Oncol; 2004 Dec; 31(6 Suppl 14):1-9. PubMed ID: 15726528 [TBL] [Abstract][Full Text] [Related]
13. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo. Elliott WL; Roberts BJ; Howard CT; Leopold WR Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790 [TBL] [Abstract][Full Text] [Related]
14. [Predictive markers for platinum-based chemotherapy]. Nakajima TE; Yamada Y Gan To Kagaku Ryoho; 2008 Feb; 35(2):185-9. PubMed ID: 18281754 [TBL] [Abstract][Full Text] [Related]
15. Platinum-complexed antitumor immunoglobulins that specifically inhibit DNA synthesis of mouse tumor cells. Hurwitz E; Kashi R; Wilchek M J Natl Cancer Inst; 1982 Jul; 69(1):47-51. PubMed ID: 6808210 [No Abstract] [Full Text] [Related]
16. Total platinum dose versus platinum dose intensification in ovarian cancer treatment. Alberts DS; Garcia DJ Semin Oncol; 1994 Apr; 21(2 Suppl 2):11-5; quiz 16, 58. PubMed ID: 8202716 [TBL] [Abstract][Full Text] [Related]
17. Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response. Blommaert FA; Michael C; Terheggen PM; Muggia FM; Kortes V; Schornagel JH; Hart AA; den Engelse L Cancer Res; 1993 Dec; 53(23):5669-75. PubMed ID: 8242622 [TBL] [Abstract][Full Text] [Related]
18. Platinum resistance. Experimental and clinical status. Los G; Muggia FM Hematol Oncol Clin North Am; 1994 Apr; 8(2):411-29. PubMed ID: 8040146 [TBL] [Abstract][Full Text] [Related]
19. Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer. Muggia FM Semin Oncol; 2004 Dec; 31(6 Suppl 15):19-24. PubMed ID: 15726535 [TBL] [Abstract][Full Text] [Related]
20. Medical therapy of advanced malignant epithelial tumours of the ovary. Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]